Sakr, Yasser http://orcid.org/0000-0003-3163-1334
Bensasi, Hatim
Taha, Ahmed
Bauer, Michael
Ismail, Khaled
Belhaj, Ghazala
Afet, Khaled M.
Munde, Dnyanwshwar
Monk, David
Buschbeck, Samuel
,
Funding for this research was provided by:
Universitätsklinikum Jena
Article History
Received: 27 January 2021
Accepted: 26 March 2021
First Online: 12 April 2021
Declarations
:
: The authors declare that they do not have conflict of interests in relation to this manuscript.
: The off-label use of camostat mesylate was recommended by the Department of Health, Abu Dhabi (PO box 5674, Abu Dhabi, UAE). Informed consents for the off-label use of camostat mesylate were obtained on admission to the hospital according to the guidelines of UAE-Ministry of health. The analysis provided in the current manuscript was done retrospectively after obtaining the approval of the responsible institutional review board (Institutional review board of Department of Health, Abu Dhabi, PO box 5674, Abu Dhabi, UAE, application number: DOH/CVDC/2020/1669, August 8th 2020), which waived informed consent for data collection and analysis due to the retrospective nature of data collection.